REG - Ergomed plc - Results of 2018 Annual General Meeting
RNS Number : 1645RErgomed plc12 June 2018PRESS RELEASE
FOR IMMEDIATE RELEASE
Results of 2018 Annual General Meeting
London, UK - 12 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.
Resolutions 1 to 5 were passed on a show of hands.
Details of proxy results were as follows:
Resolution number
Votes for
Votes against
Abstentions
1
21,318,347
Nil
Nil
2
21,317,894
Nil
453
3
21,317,894
Nil
453
4
19,056,035
Nil
2,262,312
5
21,317,894
Nil
453
Details of voting results for resolutions 6 and 7 (including proxies) were as follows:
Resolution number
Votes for
Votes against
Abstentions
6
30,158,064
2,351,500
520
7
25,689,064
6,820,500
520
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer
Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRAGEALKAFSDPEFF
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement